Insider William Doherty Sells 273,000 APH Shares; New 113k Rule 144 Notice
Rhea-AI Filing Summary
Amphenol Corporation (APH) filed a Form 144 reporting a proposed Rule 144 sale of 113,000 common shares through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $12,462,837.80 and 1,220,921,111 shares outstanding. The filing shows these shares were acquired on 08/11/2025 by exercise of options under a registered plan and payment was made in cash on the same date.
The filing also lists recent sales by the named seller, William Doherty: 113,000 shares sold on 08/08/2025 for $12,304,750.80 and 160,000 shares sold on 05/30/2025 for $14,326,512.00, totaling 273,000 shares and $26,631,262.80 in gross proceeds during the past three months. The notice includes the seller's representation that no undisclosed material adverse information exists.
Positive
- None.
Negative
- None.
Insights
TL;DR: Rule 144 notice shows insider-option exercise and planned sale of 113,000 APH shares; recent insider sales total 273,000 shares.
The Form 144 documents a planned disposition of 113,000 Amphenol shares with an aggregate market value of $12.46M, executed through Morgan Stanley Smith Barney LLC and slated for the NYSE. The securities were acquired by option exercise on 08/11/2025 with cash payment recorded the same day. The filing also discloses two prior sales by William Doherty totaling 273,000 shares and $26.63M in gross proceeds in the past three months. From a market-impact perspective, the amounts are material in dollar terms but represent a small fraction of the 1,220,921,111 shares outstanding.
TL;DR: Form discloses option exercise and sales by William Doherty; filing includes seller's declaration of no undisclosed material adverse information.
The filing is procedurally complete for a Rule 144 notice: it identifies the broker, the number of shares, acquisition method (exercise under a registered plan on 08/11/2025), and payment method (cash). It also records recent dispositions by the named seller and contains the standard signature representation that the seller is not aware of undisclosed material adverse information. These elements support regulatory compliance and public disclosure obligations tied to insider dispositions.